세계의 차세대 항체 의약품 시장 보고서(2025년)

Next-generation antibody drugs are advanced therapeutic antibodies developed to target specific antigens with greater precision and efficacy, often incorporating innovative technologies such as bispecific antibodies or antibody-drug conjugates. These drugs aim to enhance disease treatment outcomes by improving targeting abilities and reducing side effects.

The main product types of next-generation antibody drugs include monoclonal antibodies, bispecific antibodies, antibody-drug conjugates, and others. Monoclonal antibodies are identical copies of a single antibody, created by cloning a unique immune cell, and are used to treat various conditions such as cancer and autoimmune disorders. Their mechanisms of action include checkpoint inhibitors, immune modulators, receptor blockers, targeted cytotoxic agents, and neutralizing antibodies. Delivery methods for these drugs include intravenous (IV), subcutaneous, intramuscular administration, oral formulations, and transdermal delivery systems. They are applied in oncology, autoimmune diseases, infectious diseases, and other areas, and are used by hospitals, research institutes, specialty clinics, and other healthcare providers.

The next generation antibody drug market research report is one of a series of new reports from The Business Research Company that provides next generation antibody drug market statistics, including the next generation antibody drug industry's global market size, regional shares, competitors with the next generation antibody drug market share, detailed next-generation antibody drug market segments, market trends and opportunities, and any further data you may need to thrive in the next generation antibody drug market. This next generation antibody drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The next generation antibody drug market size has grown rapidly in recent years. It will grow from $14.26 billion in 2024 to $16.54 billion in 2025 at a compound annual growth rate (CAGR) of 16.0%. The growth during the historic period can be attributed to the increasing demand for targeted therapies, rising cancer prevalence, growing adoption of immuno-oncology therapies, heightened focus on autoimmune diseases, and expanding regulatory support.

The next generation antibody drug market size is expected to see rapid growth in the next few years. It will grow to $29.72 billion in 2029 at a compound annual growth rate (CAGR) of 15.8%. The growth in the forecast period is expected to be driven by rising demand for personalized medicine, expanding drug pipelines, increasing healthcare awareness, more research collaborations, and a growing aging population. Major trends in the forecast period include advancements in antibody-drug conjugates, technological progress in bispecific antibodies, integration of next-generation sequencing, developments in protein engineering, and advancements in gene therapy integration.

The growing emphasis on personalized medicine is anticipated to drive the expansion of the next-generation antibody-drug market. Personalized medicine tailors healthcare and treatment approaches to individual patients, considering their genetic, environmental, and lifestyle factors to provide more effective and targeted therapies. This shift toward personalized medicine is fueled by advancements in genomic sequencing, which allow for more accurate diagnoses and customized treatment plans. Next-generation antibody drugs support this trend by enabling the development of therapies tailored to a patient's unique genetic makeup and disease characteristics, enhancing efficacy and reducing side effects. For example, in February 2024, the Personalized Medicine Coalition, a U.S.-based organization promoting personalized medicine, reported that in 2023, the U.S. Food and Drug Administration (FDA) approved 16 new personalized treatments for rare diseases, up from 6 in 2022. Thus, the growing emphasis on personalized medicine is driving the next-generation antibody drug market.

Companies in the next-generation antibody drug market are focusing on developing innovative solutions, such as antibody-drug conjugates (ADCs), to improve targeted cancer therapies, enhance treatment efficacy, and minimize systemic toxicity. ADCs combine a monoclonal antibody with a cytotoxic drug via a linker, allowing the drug to specifically target tumor cells while sparing healthy tissue. For instance, in January 2024, BioNTech SE, a Germany-based biotechnology firm, partnered with Duality Biologics (Suzhou) Co. Ltd., a Chinese pharmaceutical company, to receive a Fast Track designation from the U.S. FDA for their ADC candidate, BNT325/DB-1305, intended to treat platinum-resistant ovarian cancer. This drug utilizes DualityBio's DITAC (Duality Immune Toxin Antibody Conjugates) platform, which pairs a highly potent cytotoxic payload with a monoclonal antibody, ensuring precise delivery to cancer cells. The ability of BNT325/DB-1305 to selectively target cancer cells while minimizing harm to healthy tissue is a key advantage in enhancing treatment outcomes and reducing side effects.

In March 2024, Johnson & Johnson, a U.S.-based pharmaceutical company, acquired Ambrx Biopharma for an undisclosed sum. Through this acquisition, Johnson & Johnson aims to enhance its oncology portfolio by developing advanced, targeted antibody-drug conjugates that improve outcomes and minimize side effects for patients with hard-to-treat cancers. Ambrx Biopharma is dedicated to advancing the development of next-generation antibody-drug conjugates.

Major players in the next generation antibody drug market are Actinium Pharmaceuticals Inc., Pfizer Inc., F. Hoffmann-La Roche Ltd., Bristol-Myers Squibb Company, AstraZeneca plc, GlaxoSmithKline plc, Takeda Pharmaceutical Company Limited, Gilead Sciences Inc., Amgen Inc., Boehringer Ingelheim International GmbH, Regeneron Pharmaceuticals Inc., Biogen Inc., Kyowa Hakko Kirin Co. Ltd., Samsung Biologics Co. Ltd., WuXi Biologics Inc., Akeso Inc., Xencor Inc., ImmunoGen Inc., Philogen S.p.A., Telix Pharmaceuticals Limited.

North America was the largest region in the next generation antibody drug market in 2024. The regions covered in next generation antibody drug report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the next generation antibody drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The next generation antibody drug market consists of sales of engineered monoclonal antibodies, antibody-drug conjugates (ADCs), bispecific antibodies, and related biologic therapies. Values in this market are 'factory gate' values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Next Generation Antibody Drug Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on next generation antibody drug market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for next generation antibody drug ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The next generation antibody drug market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Product Type: Monoclonal Antibodies; Bispecific Antibodies; Antibody-Drug Conjugates; Other Types
• 2) By Mechanism Of Action: Checkpoint Inhibitors; Immune Modulators; Receptor Blockers; Targeted Cytotoxic Agents; Neutralizing Antibodies
• 3) By Delivery Method: Intravenous (IV) Administration; Subcutaneous Administration; Intramuscular Administration; Oral Formulations; Transdermal Delivery Systems
• 4) By Application: Oncology; Autoimmune Diseases; Infectious Diseases; Other Applications
• 5) By End User: Hospitals; Research Institutes; Specialty Clinics; Other End Users
• Subsegments:
• 1) By Monoclonal Antibodies: Human Monoclonal Antibodies; Murine Monoclonal Antibodies; Humanized Monoclonal Antibodies; Chimeric Monoclonal Antibodies
• 2) By Bispecific Antibodies: Checkpoint Inhibitor-Based Bispecifics; Bispecific Antibodies For Cytokine Modulation; Bispecific Antibodies With Extended Half-Life Technologies
• 3) By Antibody-Drug Conjugates: Cleavable Linker Antibody-Drug Conjugates; Non-Cleavable Linker Antibody-Drug Conjugates; Site-Specific Conjugated Antibody-Drug Conjugates
• Companies Mentioned: Pfizer Inc.; F. Hoffmann-La Roche Ltd.; Bristol-Myers Squibb Company; AstraZeneca plc; GlaxoSmithKline plc
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery Format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Next Generation Antibody Drug Market Characteristics

3. Next Generation Antibody Drug Market Trends And Strategies

4. Next Generation Antibody Drug Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Trade Wars and Tariffs, And Covid And Recovery On The Market

5. Global Next Generation Antibody Drug Growth Analysis And Strategic Analysis Framework

• 5.1. Global Next Generation Antibody Drug PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Next Generation Antibody Drug Market Growth Rate Analysis
• 5.4. Global Next Generation Antibody Drug Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Next Generation Antibody Drug Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Next Generation Antibody Drug Total Addressable Market (TAM)

6. Next Generation Antibody Drug Market Segmentation

• 6.1. Global Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Monoclonal Antibodies
• Bispecific Antibodies
• Antibody-Drug Conjugates
• Other Types
• 6.2. Global Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitors
• Immune Modulators
• Receptor Blockers
• Targeted Cytotoxic Agents
• Neutralizing Antibodies
• 6.3. Global Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Intravenous (IV) Administration
• Subcutaneous Administration
• Intramuscular Administration
• Oral Formulations
• Transdermal Delivery Systems
• 6.4. Global Next Generation Antibody Drug Market, Segmentation By Application, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oncology
• Autoimmune Diseases
• Infectious Diseases
• Other Applications
• 6.5. Global Next Generation Antibody Drug Market, Segmentation By End User, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospitals
• Research Institutes
• Specialty Clinics
• Other End Users
• 6.6. Global Next Generation Antibody Drug Market, Sub-Segmentation Of Monoclonal Antibodies, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Human Monoclonal Antibodies
• Murine Monoclonal Antibodies
• Humanized Monoclonal Antibodies
• Chimeric Monoclonal Antibodies
• 6.7. Global Next Generation Antibody Drug Market, Sub-Segmentation Of Bispecific Antibodies, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Checkpoint Inhibitor-Based Bispecifics
• Bispecific Antibodies For Cytokine Modulation
• Bispecific Antibodies With Extended Half-Life Technologies
• T-Cell Engagers
• 6.8. Global Next Generation Antibody Drug Market, Sub-Segmentation Of Antibody-Drug Conjugates, By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cleavable Linker Antibody-Drug Conjugates
• Non-Cleavable Linker Antibody-Drug Conjugates
• Site-Specific Conjugated Antibody-Drug Conjugates
• 6.9. Global Next Generation Antibody Drug Market, Sub-Segmentation Of Other Types, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Teclistamab
• Mosunetuzumab

7. Next Generation Antibody Drug Market Regional And Country Analysis

• 7.1. Global Next Generation Antibody Drug Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Next Generation Antibody Drug Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Next Generation Antibody Drug Market

• 8.1. Asia-Pacific Next Generation Antibody Drug Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Next Generation Antibody Drug Market

• 9.1. China Next Generation Antibody Drug Market Overview
• 9.2. China Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Next Generation Antibody Drug Market

• 10.1. India Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Next Generation Antibody Drug Market

• 11.1. Japan Next Generation Antibody Drug Market Overview
• 11.2. Japan Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Next Generation Antibody Drug Market

• 12.1. Australia Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Next Generation Antibody Drug Market

• 13.1. Indonesia Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Next Generation Antibody Drug Market

• 14.1. South Korea Next Generation Antibody Drug Market Overview
• 14.2. South Korea Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Next Generation Antibody Drug Market

• 15.1. Western Europe Next Generation Antibody Drug Market Overview
• 15.2. Western Europe Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Next Generation Antibody Drug Market

• 16.1. UK Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Next Generation Antibody Drug Market

• 17.1. Germany Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Next Generation Antibody Drug Market

• 18.1. France Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Next Generation Antibody Drug Market

• 19.1. Italy Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Next Generation Antibody Drug Market

• 20.1. Spain Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Next Generation Antibody Drug Market

• 21.1. Eastern Europe Next Generation Antibody Drug Market Overview
• 21.2. Eastern Europe Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Next Generation Antibody Drug Market

• 22.1. Russia Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Next Generation Antibody Drug Market

• 23.1. North America Next Generation Antibody Drug Market Overview
• 23.2. North America Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Next Generation Antibody Drug Market

• 24.1. USA Next Generation Antibody Drug Market Overview
• 24.2. USA Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Next Generation Antibody Drug Market

• 25.1. Canada Next Generation Antibody Drug Market Overview
• 25.2. Canada Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Next Generation Antibody Drug Market

• 26.1. South America Next Generation Antibody Drug Market Overview
• 26.2. South America Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Next Generation Antibody Drug Market

• 27.1. Brazil Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Next Generation Antibody Drug Market

• 28.1. Middle East Next Generation Antibody Drug Market Overview
• 28.2. Middle East Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Next Generation Antibody Drug Market

• 29.1. Africa Next Generation Antibody Drug Market Overview
• 29.2. Africa Next Generation Antibody Drug Market, Segmentation By Product Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Next Generation Antibody Drug Market, Segmentation By Mechanism Of Action, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Next Generation Antibody Drug Market, Segmentation By Delivery Method, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Next Generation Antibody Drug Market Competitive Landscape And Company Profiles

• 30.1. Next Generation Antibody Drug Market Competitive Landscape
• 30.2. Next Generation Antibody Drug Market Company Profiles
  • 30.2.1. Actinium Pharmaceuticals Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. F. Hoffmann-La Roche Ltd. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. Bristol-Myers Squibb Company Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis

31. Next Generation Antibody Drug Market Other Major And Innovative Companies

• 31.1. GlaxoSmithKline plc
• 31.2. Takeda Pharmaceutical Company Limited
• 31.3. Gilead Sciences Inc.
• 31.4. Amgen Inc.
• 31.5. Boehringer Ingelheim International GmbH
• 31.6. Regeneron Pharmaceuticals Inc.
• 31.7. Biogen Inc.
• 31.8. Kyowa Hakko Kirin Co. Ltd.
• 31.9. Samsung Biologics Co. Ltd.
• 31.10. WuXi Biologics Inc.
• 31.11. Akeso Inc.
• 31.12. Xencor Inc.
• 31.13. ImmunoGen Inc.
• 31.14. Philogen S.p.A.
• 31.15. Telix Pharmaceuticals Limited

32. Global Next Generation Antibody Drug Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Next Generation Antibody Drug Market

34. Recent Developments In The Next Generation Antibody Drug Market

35. Next Generation Antibody Drug Market High Potential Countries, Segments and Strategies

• 35.1 Next Generation Antibody Drug Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Next Generation Antibody Drug Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Next Generation Antibody Drug Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer